The intratumor patterns of MET expression could be an important element to determine a successful response to targeted therapy or to predict possible tumor relapse after treatment and should be better investigated during clinical trials aiming the use of anti-MET drugs in ESCC patients. This evidence concerns the gene MET and neoplasm.